DOI   Click here for help

GtoPdb Ligand ID: 147

Synonyms: 4-DOI
Compound class: Synthetic organic
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 1
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 44.48
Molecular weight 321.02
XLogP 2.66
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(I)c(cc1CC(N)C)OC
Isomeric SMILES COc1cc(I)c(cc1CC(N)C)OC
InChI InChI=1S/C11H16INO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3
InChI Key BGMZUEKZENQUJY-UHFFFAOYSA-N
References
1. Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D, Durkin M, Hartig PR, Weinshank RL, Branchek TA. (1993)
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
Proc Natl Acad Sci USA, 90 (2): 408-12. [PMID:8380639]
2. Bai F, Yin T, Johnstone EM, Su C, Varga G, Little SP, Nelson DL. (2004)
Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor.
Eur J Pharmacol, 484 (2-3): 127-39. [PMID:14744596]
3. Branchek T, Adham N, Macchi M, Kao HT, Hartig PR. (1990)
[3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.
Mol Pharmacol, 38 (5): 604-9. [PMID:2233697]
4. Egan C, Grinde E, Dupre A, Roth BL, Hake M, Teitler M, Herrick-Davis K. (2000)
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
Synapse, 35: 144-150. [PMID:10611640]
5. Kursar JD, Nelson DL, Wainscott DB, Baez M. (1994)
Molecular cloning, functional expression, and mRNA tissue distribution of the human 5-hydroxytryptamine2B receptor.
Mol Pharmacol, 46 (2): 227-34. [PMID:8078486]
6. Nelson DL, Lucaites VL, Wainscott DB, Glennon RA. (1999)
Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors.
Naunyn Schmiedebergs Arch Pharmacol, 359 (1): 1-6. [PMID:9933142]
7. Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L. (2003)
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
Br J Pharmacol, 140 (2): 277-84. [PMID:12970106]
8. Shapiro DA, Kristiansen K, Kroeze WK, Roth BL. (2000)
Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.
Mol Pharmacol, 58 (5): 877-86. [PMID:11040033]
9. Sleight AJ, Stam NJ, Mutel V, Vanderheyden PM. (1996)
Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities.
Biochem Pharmacol, 51 (1): 71-6. [PMID:8534270]
10. Wainscott DB, Cohen ML, Schenck KW, Audia JE, Nissen JS, Baez M, Kursar JD, Lucaites VL, Nelson DL. (1993)
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
Mol Pharmacol, 43 (3): 419-26. [PMID:8450835]